Introduction {#s1}
============

Acute exacerbation of chronic obstructive pulmonary disease (COPD) refers to a severe deterioration in the condition of a COPD patient that requires a medication change due to their baseline respiratory symptoms exceeding the daily fluctuation range \[[@R01], [@R02]\]. Patients with COPD frequently experience this acute exacerbation, which can reduce their quality of life and pulmonary function, while causing greater socioeconomic burden and accelerating disease progression \[[@R03], [@R04]\]. Previous studies reported that the number of acute COPD exacerbations had an influence on mortality. Other authors reported that the mortality rate ranged greatly from lower than 22% to 49%, depending on the severity of the acute COPD exacerbation that caused the patient to be hospitalized \[[@R05], [@R06]\]. As shown, acute exacerbation of COPD has a major influence on mortality; therefore, the combined COPD assessment from Global Initiative from Chronic Obstructive Lung Disease (GOLD), published in 2011, recommended that patients who have been admitted at least once a year for acute exacerbation need to be classified as high risk (group C or D) and treated more aggressively \[[@R07]\]. It is very important to identify the risk factors associated with COPD exacerbation onset and recurrence. However, to our knowledge, studies of these high-risk groups experiencing at least once a year hospitalization are lacking in South Korea. Therefore, the authors of this study investigated the clinical features, comorbidities and mortality of high-risk patients who were diagnosed with COPD at Gachon University Gil Hospital and hospitalized at least once a year.

Materials and Methods {#s2}
=====================

Study design {#s2a}
------------

A retrospective survey was conducted on the medical records of patients who were diagnosed with COPD at Gachon University Gil Hospital between October 1999 and June 2013. First, patients with COPD were selected from the hospital's electronic medical record system according to the International Classification of Diseases (ICD) coding (ICD-9: 490-492, 494-496). Among these patients, those with the following risk factors were included in the study: smoking history and reduced pulmonary function (forced expiratory volume in 1 s (FEV~1~) to forced vital capacity (FVC) ratio (FEV~1~/FVC) lower than 0.7) \[[@R07]\]. Other lung diseases, such as asthma, lung cancer, bronchiectasis, active tuberculosis, and pleurisy, were excluded. Acute exacerbation of COPD was based on the GOLD guidelines and included outpatient visits and hospitalizations from acute events manifesting with exacerbation of respiratory symptoms that required a medication switch due to unusual changes \[[@R07], [@R08]\]. The group that was at high risk for acute COPD exacerbation consisted of patients who had been hospitalized at least once for acute COPD exacerbation, per the GOLD guidelines \[[@R07]\]. The enrolled patients' age, gender, body weight, body mass index (BMI), smoking status, comorbidities, medications administered, follow-up period, and survival status were analyzed. The patients' comorbidities were defined as having already been diagnosed and being treated, while laboratory test result analyses used test results under stable conditions and from outpatient visit- or hospitalization-exacerbated conditions.

Statistical analysis {#s2b}
--------------------

Data were expressed mean ± standard deviation. Continuous data were done by the Student's *t*-test and categorical data were compared by the Pearson's Chi-square test. Differences were considered significant when the P value was less than 0.05. Statistical analyzed were performed by IBM SPSS Statistics 21.

Results {#s3}
=======

Clinical characteristics, blood tests and pulmonary function test {#s3a}
-----------------------------------------------------------------

A total of 606 patients were enrolled in the study, of which 321 were assigned to the exacerbation group. The mean age of the exacerbation group was 73.14 years, which was significantly higher than the mean of 70.7 years in the non-exacerbation group (P = 0.000). Meanwhile, the mean body weight (P = 0.003) and BMI (P = 0.019) were significantly lower in the exacerbation group. The laboratory test results indicated significantly lower white blood cell (WBC) counts (P = 0.002) and serum albumin concentrations (P = 0.007) in the exacerbation group ([Table 1](#T1){ref-type="table"}).

###### Clinical Characteristics of All COPD Patients

  Baseline characteristics    Exacerbation (N) (N = 285)   Exacerbation (Y) (N = 321)   P-value
  --------------------------- ---------------------------- ---------------------------- ---------
  Male/female (n)             247/38                       266/55                       0.246
  Age (years)                 70.07 ± 8.98                 73.14 ± 9.35                 0.000
  Height (cm)                 164 ± 7.34                   163 ± 8.63                   0.121
  Weight (kg)                 58.9 ± 10.1                  56.5 ± 10.4                  0.003
  Body mass index (kg/m^2^)                                                             0.019
    BMI \< 18.5               42                           69                           
    18.5 ≤ BMI \< 25          192                          214                          
    25 ≤ BMI                  52                           38                           
  WBC (10^3^/mm^3^)           8,035.63 ± 3,145.68          5,969.47 ± 3,711.41          0.002
  Serum albumin               4.13 ± 0.43                  4.02 ± 0.54                  0.007
  CRP                         1.32 ± 2.53                  1.31 ± 1.52                  0.984
  Pulmonary hypertension      31.04 ± 20.83                33.58 ± 11.96                0.162
  Pack-years                  41.19 ± 19.09                44.43 ± 29.78                0.211

Values are presented as the mean ± standard deviation unless otherwise indicated. P-values were generated by Student's *t*-tests for continuous variables and Chi-squared tests for categorical variables.

Pulmonary function tests indicated the exacerbation group showed significantly lower FVC, FEV~1~, FEV~1~/FVC, and forced expiratory flow 25-75% (FEF25-75) values while showing a significantly high at GOLD III and IV stage ([Table 2](#T2){ref-type="table"}). The most common comorbidity for all patients was cardiovascular disease, including hypertension and ischemic heart disease, while a significantly higher number of diabetes (P = 0.012) and benign prostatic hyperplasia (P = 0.001) cases were found in the exacerbation group ([Table 3](#T3){ref-type="table"}).

###### Pulmonary Function Test of All COPD Patients

  Variable                                        Exacerbation (N) (N = 285)   Exacerbation (Y) (N = 321)   P-value
  ----------------------------------------------- ---------------------------- ---------------------------- ---------
  Pulmonary function test (post-bronchodilator)                                                             
    FVC (L)                                       2.82 ± 1.07                  2.30 ± 0.81                  0.000
    FVC (%)                                       77.66 ± 18.94                67.43 ± 2.68                 0.000
    FEV~1~ (L)                                    1.45 ± 0.60                  1.10 ± 0.48                  0.000
    FEV (%)                                       58.34 ± 20.93                48.10 ± 21.37                0.000
    FEV~1~/FVC (%)                                51.48 ± 11.38                47.74 ± 10.84                0.000
    FEF25-75 (%)                                  25.84 ± 16.21                21.83 ± 14.89                0.002
  GOLD stage                                                                                                0.000
    I                                             43                           33                           
    II                                            144                          99                           
    III                                           83                           125                          
    IV                                            16                           64                           

Values are presented as the mean ± standard deviation unless otherwise indicated. P-values were generated by Student's *t*-tests for continuous variables and Chi-squared tests for categorical variables. FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; FEF25-75: forced expiratory flow at 25-75%; GOLD stage: global initiative for chronic obstructive pulmonary disease stage.

###### Comorbidities of All COPD Patients

  Variable                        Exacerbation (N) (N = 285)   Exacerbation (Y) (N = 321)   P-value
  ------------------------------- ---------------------------- ---------------------------- ---------
  Comorbidities                                                                             
    Diabetes mellitus             30                           55                           0.012
    Hypertension                  98                           118                          0.289
    Benign prostate hypertrophy   14                           40                           0.001
    Ischemic heart disease        37                           36                           0.299
    Cerebrovascular accident      9                            12                           0.432
    Lung cancer                   4                            1                            0.153
    Other cancer                  16                           13                           0.242

Other cancer: stomach cancer, bladder cancer, breast cancer, prostate cancer, ovary cancer.

Comparison of clinical characteristics and pulmonary function test between high-risk patients for COPD exacerbation {#s3b}
-------------------------------------------------------------------------------------------------------------------

A total of 61 patients who had been hospitalized at least once in a year met the criteria for the high-risk group, equivalent to group C or D according to the combined COPD assessment criteria. Among these patients, 21 were in the non-survivor group and 40 were in the survivor group. There was no statistically significant difference in age, gender, or smoking history (pack-years) between the two groups. The mean observation period was 1,509.67 days, and there was no statistically significant difference between the non-survivor (1,448.38 days) and survivor (1,541.85 days) groups (P = 0.763). A comparison of the average number of annual acute exacerbation events between the two groups showed that the non-survivor group had a higher number of such events than the survivor group, but the difference was not statistically significant (P = 0.143). Moreover, there were no significant differences between the two groups with respect to the drug treatment in stable periods (inhaled short-acting anticholinergic, inhaled long-acting anticholinergic, inhaled long-acting β2-agonist, inhaled long-acting β2-agonist with inhaled corticosteroid, methylxanthine, systemic corticosteroid) used for treating COPD ([Table 4](#T4){ref-type="table"}).

###### Follow-Up Time and Medications of High-Risk Group Who Survived or Died During Follow-Up

                                                               All patients (N = 61)   Non-survivor (N = 21)   Survivor (N = 40)   P-value
  ------------------------------------------------------------ ----------------------- ----------------------- ------------------- ---------
  Follow-up time (days)                                        1,509.67                1,448.38                1,541.85            0.763
  Number of AE\* (years)                                       1.46                    1.66                    1.35                0.143
  Medication                                                                                                                       
    Short acting anticholinergic\*\*                           12                      5                       7                   0.618
    Long acting anticholinergic\*\*                            36                      11                      25                  0.340
    Long acting β2-agonist\*\*                                 19                      7                       12                  0.882
    Long acting β2-agonist (with inhaled corticosteroid)\*\*   30                      10                      20                  0.665
    Theophylline                                               40                      14                      26                  0.914
    Doxophylline                                               23                      6                       17                  0.235
    Systemic corticosteroid                                    32                      14                      18                  0.160

AE: acute exacerbation. \*Inhaler.

Comparison of comorbidities and blood test between high-risk patients for COPD exacerbation {#s3c}
-------------------------------------------------------------------------------------------

Among the patients in the high-risk group whose comorbidity at the time of diagnosis was identifiable, the non-survivor group had a higher number of comorbidities than the survivor group (2.83 vs. 1.88, P = 0.020), with the most common comorbidity being cardiovascular disease, including hypertension and myocardial infarction. A severity assessment based on the Charlson comorbidity index (CCI) \[[@R09]\] showed that scores of 1 (moderate), 2 (severe) and 3 or greater (very severe) were seen in 16, 14, and two patients in the survivor group, respectively, and five, six, and seven patients in the non-survivor group, respectively (P = 0.018) ([Table 5](#T5){ref-type="table"}). In comparison to the moderate group (score of 1), the mortality rate ratio (MRR) was 1.543 (95% CI: 0.389 - 6.115, P = 0.537) in the severe group (score of 2) and 12.600 (95% CI: 1.966 - 80.757, P = 0.008) in the very severe group (score of 3 or greater). Diabetes was found in six patients in the non-survivor group and 15 patients in the survivor group. Five patients in the survivor group had benign prostatic hypertroplasia, whereas no patients in the non-survivor group had it. Cancer was found in five patients in the non-survivor group (stomach cancer with bladder cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer), which was significantly higher than the one patient with cancer (prostate cancer) found in the survivor group (P = 0.015) ([Table 5](#T5){ref-type="table"}).

###### Comorbidities of High-Risk Group Who Survived or Died During Follow-Up

                                  All patients (N = 52)   Non-survivor (N = 18)   Survivor (N = 34)   P-value
  ------------------------------- ----------------------- ----------------------- ------------------- ---------
  Number of comorbidities         2.21                    2.83                    1.88                0.020
  Comorbidities                                                                                       
    Hypertension                  23                      9                       14                  0.542
    Ischemic heart disease        3                       2                       1                   0.272
    Benign prostate hypertrophy   5                       0                       5                   0.150
    Diabetes mellitus             21                      6                       15                  0.451
    Cancer                        6                       5                       1                   0.015
  Charlson comorbidity index                                                                          0.018
    1 (moderate)                  23                      5                       18                  
    2 (severe)                    20                      6                       14                  
    3 (very severe)               9                       7                       2                   

Cancer: stomach cancer with bladder cancer, lung cancer, breast cancer, prostate cancer, ovary cancer.

The two groups did not have differences in erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hsCRP) concentration, or total white blood cell (WBC) during hospitalization, but the non-survivor group had a significantly higher neutrophil percentage (P = 0.025) and a significantly lower lymphocyte percentage (P = 0.011) in complete blood cell (CBC). Especially in stable conditions, the non-survivor group had a significantly higher hsCRP (P = 0.025) concentration and neutrophil percentage (P = 0.036) in CBC, and a significantly lower lymphocyte percentage (0.005) in CBC than the survivor group ([Table 6](#T6){ref-type="table"}).

###### ESR, CRP and CBC of High-Risk Group Who Survived or Died During Follow-Up

                        All patients   Non-survivor   Survivor     P-value
  --------------------- -------------- -------------- ------------ ---------
  Hospitalization                                                  
    ESR                 34.1370        31.9371        35.8970      0.532
    hsCRP               6.6225         6.4681         6.7386       0.844
    WBC (10^3^/mm^3^)   11.5505        11.1554        11.8367      0.499
    Neutrophil (%)      73.7187        76.7963        71.4901      0.025
    Neutrophil count    8,650.7538     8,705.4729     8,611.1296   0.917
    Lymphocyte (%)      16.0222        13.5863        17.7863      0.011
    Lymphocyte count    1,772.5236     1,450.1176     2,005.9904   0.003
  Stable                                                           
    ESR                 24.3009        22.9476        25.0903      0.798
    hsCRP               1.0400         1.8273         0.5469       0.025
    WBC (10^3^/mm^3^)   9.3930         10.2663        8.9251       0.174
    Neutrophil (%)      65.4005        70.0139        62.9289      0.036
    Neutrophil count    6,310.6560     7,197.2366     5,835.7021   0.107
    Lymphocyte (%)      23.4416        18.4410        25.9657      0.005
    Lymphocyte count    2,056.1535     1,890.0601     2,145.1321   0.201

ESR: erythrocyte sedimentation rate; hsCRP: high-sensitivity C-reactive protein.

Discussion {#s4}
==========

Because existing studies had reported that acute exacerbation of COPD was the primary cause of increased mortality, GOLD-classified patients admitted at least once a year for acute exacerbation of COPD were added to the group at high risk for COPD exacerbation (group C or D) \[[@R03], [@R07], [@R10]\]. Therefore, it is necessary to understand these patients' characteristics and administer active care; however, to our knowledge, studies of patients at high risk for COPD exacerbation are still limiting. This study is significant because it studied the factors that induce mortality in patients at high risk for COPD exacerbation.

Previous study reported that comorbidity was associated with the survival of patients with COPD \[[@R11]\]. Many studies also reported that comorbidity, particularly cardiovascular disease, was associated with the survival of patients with COPD \[[@R10], [@R12]\]. In our study, exacerbation was closely related with higher age, lower BMI, lower albumin and lower pulmonary function. The overall number of comorbidities was significantly associated with mortality (P = 0.020). A comparison of the two groups (non-survivors vs. survivors), classified by severity according to the CCI showed a significant difference between the groups (P = 0.018). The MRR of the very severe group relative to the moderate group was 12.600 (95% CI: 1.966 - 80.757, P = 0.008), which was consistent with findings from previous studies that an increase in the CCI was associated with a less favorable prognosis \[[@R15]\]. Plasma CRP concentration and neutrophil count in CBC, which have been studied extensively, are inflammatory biomarkers of COPD that can be tested economically and easily through a blood test in a clinical setting \[[@R16]\]. Previous reports have indicated that WBC count, along with CRP, fibrinogen, and TNF-α concentrations are generally elevated in patients with COPD \[[@R03], [@R16], [@R17]\]. It was reported that when COPD is stable, CRP is proportional to age, weight, dyspnea, and quality of life, while being inversely proportional to motor ability and FEV1 \[[@R18], [@R19]\]. In a study by Hana and colleagues, CRP concentration and neutrophil count were significantly elevated in hospitalized exacerbation cases \[[@R03]\]. Other author also reported that CRP concentration and neutrophil count were significantly higher in severe COPD exacerbation cases than in stable COPD cases \[[@R16]\]. In a study by Man and colleagues that examined the relationship between CRP and the mortality rate attributed to COPD, serum CRP concentration was a significant predictive factor of the mortality rate; it also increased the mortality rate attributed to cancer and cardiovascular diseases \[[@R20]\]. In a study by de Torres and colleagues that examined 218 patients with moderate to very severe COPD under stable conditions, serum CRP concentrations were higher in the mortality group but the difference was not statistically significant \[[@R21]\]. In the present study, which examined patients at high risk for acute exacerbation of COPD, CRP concentrations measured under stable conditions were significantly higher in the non-survivor group (P = 0.025). This study has some limitations. This study was conducted in one university hospital. Inflammatory biomarkers such as hsCRP concentration and WBC count were being measured, but other inflammation-related biomarkers, such as interleukin (IL)-6, IL-8, and TNF-α were not sufficiently investigated. Through the findings in this study, the researchers were able to identify the total number of comorbidities at the time of diagnosis and the hsCRP concentration measured under stable conditions as potential predictive factors for mortality in patients who were hospitalized for acute exacerbation of COPD.

In conclusion, patients at high risk for acute COPD exacerbation need to be diagnosed for comorbidities and administered thorough treatment and management of such comorbidities. It is believed that regular measurements of systemic inflammatory indicators, including hsCRP, neutrophils, and lymphocytes, during follow-up observations will help predict a patient's prognosis. A large-scale prospective study on this subject matter is necessary.
